Background: Despite receiving identical reimbursement for treating heart disease patients with bare metal stents (BMS) or drug-eluting coronary stents (DES), cardiologists' use of the new technology (DES) may have varied by patient payer type as DES diffused. Payer-related factors that differ between hospitals and/or differential treatment inside hospitals might explain any overall differences by payer type.
M edical innovation has contributed significantly to increases in longevity, but has also fueled the rapid growth of health care spending. 1 At the same time, previous studies have highlighted the essential role health insurance plays in access to medical care: individuals without any coverage and those with less-generous Medicaid coverage have less access to providers and, even conditional on access, use less medical care than those with Medicare or private insurance. [2] [3] [4] We consider the relationship between insurance and access to innovation in the context of drug-eluting coronary stents (DES), a beneficial but expensive 5 new medical technology that supplanted the existing technology, bare metal stents (BMS), as the primary device implanted for percutaneous coronary interventions (PCI).
DES make a particularly interesting case study because their use over the short time they have been available has fluctuated dramatically. DES were initially available outside of clinical trials after Food and Drug Administration approval of the first DES in April 2003. After randomized trials demonstrating clinical superiority, 6, 7 DES captured 55% of the coronary stent market by the end of 2003 and achieved nearly complete market penetration at the beginning of 2005. Rapid adoption occurred despite the absence of favorable financial incentives for providers. Cardiologists were reimbursed the same for DES as for BMS, and hospitals' Medicare profit margins were lower for DES than for BMS. 8 Patients faced a higher effective price for DES as well; patients receiving DES required a prolonged regimen of clopidogrel, an antiplatelet therapy.
Beginning in 2006, however, research suggested that DES had slightly higher long-term rates of myocardial infarction, death, and hospital readmission than BMS. 9, 10 From a peak market share of 90% in August 2006, DES use declined as providers apparently responded to concerns about DES long-term safety and curtailed off-label DES use. 11 In response to the DES safety warnings, recommendations for supplementing DES with clopidogrel were extended from 3 to 6 months to 12 months or longer. 12 DES use rebounded in 2008, 13 perhaps due in part to the availability of the first second-generation DES, which showed improved patient outcomes. 14 The history of DES points to several potential sources of differences in DES use by payer type. Studies of medical care disparities suggest they exist, in part, because vulnerable patient populations are treated by lower quality providers (ie, between-hospital differences). 15 One reason differences in DES use by payer type might occur is if uninsured and Medicaid patients were treated disproportionately in hospitals that were slow in adopting innovations related to PCI, including DES and new knowledge about DES risks. In such cases, DES use at these hospitals would have increased more slowly during the initial diffusion period and declined less rapidly subsequent to the safety warnings compared with other hospitals. Similarly, if the hospitals that disproportionately treated uninsured and Medicaid patients had fewer resources or less enthusiasm for high-cost technologies, DES use at these hospitals would have increased more slowly during the adoption period and decreased more rapidly after the safety warnings.
Alternatively, differences by payer could have arisen from differences in treatment decisions inside the same hospitals (ie, within-hospital differences). Reimbursement considerations may have prompted hospitals to expand DES use among uninsured and Medicaid-insured patients more slowly than others. Also, nonfinancial factors may have played a role; after the safety warnings, physicians may have placed increased weight on their perceptions of patients' likelihood of adherence, prescription coverage generosity, or preferences for a long-term regimen of clopidogrel in deciding whether to use DES. This would have amplified within-hospital differences beginning in mid-2006.
Although previous work has reported lower use of DES among Medicaid and uninsured patients relative to privately insured patients, there has been no investigation of the sources of these payer differences. 11, [16] [17] [18] [19] [20] Our study uses nationally representative data covering from 2003 to 2008 to better understand the overall differences in DES use across payer by separately evaluating the between-hospital and within-hospital sources of variation.
METHODS
We assessed differences across payer types in DES use among patients who received a coronary stent between the initial approval of DES, at the beginning of Q2 2003, through the end of 2008. The payer types we considered were: no insurance, Medicaid, Medicare, and private insurance.
Data
We used data from the Nationwide Inpatient Sample (NIS), the largest publicly available all-payer inpatient database in the United States. 21 It includes administrative records for all hospitalizations in a randomly selected, national sample of nonfederal, acute care hospitals. The 2008 NIS, the most recent version available at the time of the study, contains information on more than 8 million discharges occurring at 1056 hospitals in 42 states, corresponding to nearly 20% of all admissions to United States nonfederal hospitals.
Sample
We restricted our analysis to hospitalizations in which the patient had a primary or secondary procedure code indicating the insertion of BMS or DES (International Classification of Diseases, 9th Edition Clinical Modification procedure codes 36.06 and 36.07, respectively). We identified 876,480 patient records in the 2003 to 2008 combined NIS data, indicating that coronary stent insertion occurred during hospitalization. To minimize data coding errors, we excluded patient records that had missing data for sex (n = 92) or payer (n = 1029) or that were from hospitals with fewer than 5 PCIs coded in the same calendar year (n = 163). We excluded patients with rare payer types coded as "Other" (Worker's Compensation, CHAMPUS, CHAMP-VA, Title V, and other government programs) (n = 23,516). We also excluded records from hospitals that used either all DES or all BMS in a given year (n = 1459), because our methodology requires within-hospital variation in stent type. The final study cohort consisted of 850,221 (97.0%) admissions at 984 hospitals in 41 states.
Measures
The primary study outcome was a dichotomous measure of whether a patient received at least 1 DES versus receiving only BMS. We categorized patient payer type into 1 of 4 exclusive groups: private (including Blue Cross, commercial carriers, and private Health Maintenance Organizations and Preferred Provider Organizations), Medicare (both fee-for-service and managed care), Medicaid (both fee-for-service and managed care), or uninsured (selfpay or charity), based on the coding of the expected primary payer collected in the NIS. Note that Medicare is the primary payer for Medicare-Medicaid dual-eligible patients. 22 The NIS assigns hospitalizations to calendar quarters based on the date of hospital discharge.
Analysis
Trends in the use of DES were compared on a quarterly basis across payers over the study period. The model capturing the overall quarter-specific differences between payers was specified as:
where Payer j is an indicator for whether the patient had insurance type j ( j 2 {Medicare, Medicaid, uninsured}), and Qtr is a vector of 22 calendar quarters (Q2 2003 was omitted). The model specification also included patient-level characteristics (age, sex, race/ethnicity, quartile of median household income of residential ZIP code, weekend admission, admission severity, transfer from another hospital, indication (acute myocardial infarction, acute coronary syndrome, or neither), and a set of 29 comorbid conditions developed by Elixhauser et al 23 ) and hospital-level characteristics (ownership, teaching status, annual PCI volume, Census region, and rural location). We included additional controls for whether the patient was 65 years or older and did not have Medicare, and whether the patient was younger than 65 and did have Medicare.
To quantify the between-hospital and within-hospital differences in DES use across payer types, we specified a hybrid-fixed effects model 24, 25 :
This approach adds a measure of the hospital-level proportion of stent patients receiving DES for each payer type (Payer hj ) and its interaction with Qtr. In this specification, the patient-level payer indicators capture the within-hospital associations (ie, the average difference in DES use between otherwise identical patients with different payer types treated at the same hospital), whereas the hospital-level payer share measures capture the between-hospital associations (ie, the average difference in DES use between 2 identical patients treated at hospitals that vary only in the payer mix of their stent patients). 26 To facilitate interpretation we converted the logistic regression results to the probability scale. Using the estimated coefficients, we calculated quarter-specific differences in the predicted probability of DES use for each payer type relative to private insurance whereas holding the remaining covariates at their mean values in the full cohort. For the overall and within-hospital differences, we varied only the patient-level payer indicators in calculating the predicted probabilities. For the between-hospital differences, we varied only the hospital-level payer proportions; in the baseline scenario, they were set to their mean values, and, in the alternate scenario, the hospital-level proportion of the alternate payer type was increased by 10% points whereas the privately insured proportion was reduced by 10% points from their mean values. We used the Delta method to calculate 95% confidence intervals around these quarterspecific, across-payer differences in predicted probabilities.
Estimation of the logistic regression models incorporated survey weights to account for the complex NIS sampling scheme. As a sensitivity check, to account for the clustering of patients within hospitals we estimated hierarchical logistic regressions with random intercepts. The results were qualitatively unchanged.
Two-tailed tests with P < 0.05 were used to establish statistical significance. Analyses were conducted using Stata 11.2 (College Station, TX). The study was deemed Health Insurance Portability and Accountability Act-compliant and exempted from Institutional Review Board review.
RESULTS
Of the 4.1 million hospitalizations involving a coronary stent in the study cohort, most were for patients with Medicare (52.2%) or private insurance (38.5%) ( Table 1) . Only a small portion of stent procedures involved patients with Medicaid (4.9%) or no insurance (4.4%). Patient and hospital characteristics varied significantly across payer types. As expected, Medicare patients were older on an average. Greater proportions of Medicaid patients were female, black, Hispanic, who resided in low-income areas, and were admitted to teaching hospitals in the Northeast. Greater proportions of uninsured patients were admitted on the weekend, for nonelective procedures, and to rural hospitals in the South.
Overall Trends in DES Use by Payer
Unadjusted results reported in Figure 1 This overall pattern held regardless of payer type, but there were differences across payers throughout all 4 periods. DES use among Medicare patients tracked privately insured patients' use, but was typically a few percentage points lower. Uninsured and Medicaid patients were less likely to receive DES than privately insured patients throughout, and lagged behind Medicare patients except during the saturation period.
As suggested in Table 1 , the unadjusted differences in Figure 1 may be attributable to other patient and hospital characteristics that vary by payer type. We therefore present results that adjust for these characteristics in Figures 2-4 , which show the quarterly differences in DES use relative to private insurance (the solid lines) and their 95% confidence intervals (the dashed lines). The underlying data points are provided in the online Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A236. The overall differences in DES use by payer type remained after adjustment (Fig. 2) . The adjusted DES rates for both Medicaid and the uninsured were significantly below private insurance for nearly the entire study period. Likewise, Medicare was predominantly below private insurance.
Moreover, Figure 2 shows that differences in rates of DES use by payer type varied over time. During the adoption period, DES use among Medicare beneficiaries was as much 
Within-Hospital and Between-Hospital Differences in DES Use by Payer
The trends in within-hospital adjusted differences in DES use paralleled the overall differences ( Fig. 3 ). Rates of DES use among Medicare patients were similar to or slightly lower than use among privately insured patients when treated at the same hospitals through 2006 (range: À 1.5 to 1.8% points), but notably lower by Q4 2008 (4.6% points). Medicaid and uninsured patients also received DES at lower rates than privately insured patients at the same hospitals. The within-hospital gaps were largest in Q3 2003 (Medicaid: 11.9, uninsured: 10.9% points) and Q4 2008 (Medicaid: 12.8%, uninsured: 20.7% points), and smallest in Q4 2004 (Medicaid: 1.4%, uninsured: 1.1% points).
In sharp contrast, the between-hospital adjusted differences in DES use by payer were small and rarely significant (Fig. 4 ). Patients at hospitals with higher shares of Medicaid and uninsured stent patients generally received DES at the same rates as patients at average hospitals. The exception occurred during Q1 to Q4 2008, when hospitals treating higher proportions of Medicare patients had significantly higher relative DES use overall. Specifically, during this time, DES use was 2.1% to 3.5% points higher among patients treated at hospitals with a 10% point higher share of Medicare patients (and a 10% point lower share of privately insured patients) relative to hospitals with the mean payer mix.
DISCUSSION
Medicaid and uninsured patients were consistently less likely to receive DES than were privately insured patients during 2003 to 2008, even after accounting for a range of patient and hospital characteristics. Medicare patients were also less likely to receive DES, though the gap with privately insured patients was smaller. The differences fluctuated over time as the popularity of DES relative to BMS increased and decreased. They were large after DES approval, narrowed but were still present as DES use reached saturation, and increased again as DES use declined after safety concerns became widespread in the second half of 2006. By the end of 2008, as DES use increased, the gaps also increased. Furthermore, variation in DES use by payer was attributable almost entirely to differential treatment within hospitals, and the within-hospital differences were larger in Q4 2008 than at any other time.
Our finding that payer differences in DES use principally reflected intrahospital differences in treatment is consistent with evidence that hospitals seem to treat cardiovascular patients differently depending on the generosity of their insurance coverage. 27, 28 Further, payer differences in DES use did not stem from Medicaid and uninsured patients concentrating in hospitals with lower DES usage, ruling out a number of potential explanations and implying that policies aimed at redirecting patients to high-use hospitals would not have ameliorated these differences. 18 Understanding the within-hospital, between-payer differences in DES use depends critically on context-specific features. Importantly, physicians receive the same reimbursement for using DES as for BMS. 8 This equality presumably eliminates their direct financial incentives, which have led to treatment differences in other contexts. 29 Even after adjustment for other patient-level demographic and socioeconomic factors, payer type could nevertheless influence physicians' perceptions of patients that in turn affect their choice of stent. One specific concern relates to patient adherence to long-term antiplatelet therapy after DES, which was magnified after the safety warnings in 2006. [30] [31] [32] [33] Physicians may have anticipated that Medicaid and uninsured patients were less likely than privately insured patients to adhere to clopidogrel, perhaps because of perceived or actual differences in patients' out-of-pocket costs or other reasons.
It is also possible that the relationship between payer type and stent choice was shaped by hospitals' financial incentives. Across a range of high-cost drugs and devices known as "physician preference items," there is a well known misalignment of incentives among physicians, who choose which drugs and devices to use, and hospitals, which bear the cost. 34 Hospital acquisition prices for DES have been much higher than for BMS, 35 resulting in lower or even negative hospital profit margins for DES for all payer types.
Because the margins for DES were even lower relative to BMS for Medicaid and uninsured patients, hospitals may have effectively encouraged cardiologists to concentrate on DES use among higher-paying patients, particularly during the early supply shortages. 36 Although absent from our data, hospital managers have adopted a number of strategies to influence physicians' device use, including value analysis teams 34 and gainsharing. 37 Our analysis is limited in 2 important ways. First, the NIS does not include information on all factors, including clinical data that physicians might consider in selecting stents. As a result, our estimates might suffer from omitted variables bias, and we cannot reach a definitive conclusion about the causes of within-hospital variation in DES use by payer. Also, because the NIS data do not reliably identify physicians, we cannot determine whether the within-hospital differences were created by differences within or between cardiologists.
Second, we cannot say whether differences in DES use imply differences in quality of care. As our data do not identify on-label versus off-label use, we cannot distinguish whether differences reflect under-treatment for some payer types, over-treatment for others, or appropriate care in some or many instances. Given the importance of patient adherence with antiplatelet therapy, however, even with information on clinical appropriateness we could not determine whether a specific patient would have benefited more from DES or BMS. Reasonable physicians might select DES for 1 patient they thought was likely to adhere to 5%   10%  2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 clopidogrel, and select BMS for another patient deemed unlikely to adhere, even if the 2 patients were otherwise identical. A broader issue is whether differences in the use of DES by payer type reflect a systemic health care disparity. This depends in part on establishing the incremental value of DES over BMS. Although the principal benefit of DES has been the reduction of restenosis risk, scientific understanding of their risks has evolved even as technology has improved. The value of DES depends on a number of variables and has changed over time, which may be why physicians' perceptions of DES value vary significantly.
Whether our findings indicate a systemic disparity depends also on whether patients with generous insurance are better positioned to accrue the benefits of DES. As suggested by Goldman and Lakdawalla, 38 new technologies are likely to exacerbate disparities when they are complicated to use, because more educated and wealthier patients are better able to manage the demands of a complicated treatment and therefore will be selected disproportionately for it. Because DES requires a substantially longer regimen of clopidogrel than BMS, physicians may have limited DES to individuals they thought were more likely to adhere to that regimen, and they may have used payer type as a proxy for adherence. This would explain why the gaps in DES use by payer type grew largest at the end of 2008, as physicians responded to safety warnings and increasingly restricted DES to patients who perceived as being clopidogreladherent. However, little is known about either the accuracy of clinicians' predictions of long-term medication adherence or whether social factors are reliable predictors of adherence. Data from 1 center indicate that clopidogrel adherence rates for 1 year post-stent varied little by stent type or payer type. 20 Regardless, differences in the use of innovative technologies based on socioeconomic factors like payer type are likely to occur whenever technology requires physicians to reserve the treatment for patients they judge to have adequate abilities and resources.
During its initial diffusion period and since safety concerns came to light, access to an important new cardiovascular technology differed substantially by payer. Specifically, rates of DES use among the uninsured and Medicaid populations were well below privately insured patients. Although our understanding of the specific mechanisms at work is incomplete, these gaps are almost entirely attributable to differential treatment within hospitals and independent of between-hospital differences. Although it does not necessarily follow that physicians based their use of DES directly on patients' payer type, it is unlikely that Medicaid and uninsured patients were less likely than privately insured patients to be clinically appropriate candidates for DES. Therefore, the observed differences in DES use across payers likely stemmed from differences in physicians' judgments about patient adherence and/or concerns about hospital finances. 
